The Third Circuit has ruled in favor of Amgen Inc., allowing the biotechnology firm to continue with its subpoena efforts against a competitor over allegations of patent infringement. The court decided that the case was not within its jurisdiction for appeal because the lower court’s decision pertaining to discovery was deemed premature for such a process.
This decision is a significant development in Amgen’s ongoing legal strategy, potentially impacting its competitive position in the biotechnology landscape. More details on the case can be found by reviewing the original piece at Law360.